WHAT IS CLAIMED:

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating a gastrointestinal disorder wherein said pharmaceutical composition is to be administered to a patient independently of the intake or consumption of food or meal;

wherein said pharmaceutical composition comprises a therapeutically effective amount of a dosage form comprising:

(a) a first solid particle, wherein said first solid particle comprises dexlansoprazole and a first enteric coating, wherein the first enteric coating releases the dexlansoprazole from the solid particle at a pH of about 5.0 to about 5.5; and

(b) a second solid particle, wherein said second solid particle comprises dexlansoprazole and a second enteric coating, wherein the second enteric coating releases the dexlansoprazole from the solid particle at a pH of about 6.2 to about 6.8; and

wherein the first solid particle is present in the pharmaceutical composition in an amount of from about 15% to about 50% by weight of the pharmaceutical composition and the second solid particle is present in the pharmaceutical composition in an amount of from about 50% to about 85% by weight of the pharmaceutical composition; and

wherein the gastrointestinal condition is heartburn, inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding peptic ulcer, a duodenal ulcer, infectious enteritis, colitis, diverticulitis, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, *Helicobacter pylori* associated disease, short-bowel syndrome, hypersecretory states associated with systemic mastocytosis or basophilic leukemia or hyperhistaminemia or combinations of any of the above disorders.

2. The use of claim 1, wherein the first enteric coating releases the dexlansoprazole at a pH of about 5.5.

3. The use of claim 2, wherein the first enteric coating comprises a methacrylic acid copolymer dispersion.

4. The use of any preceding claim, wherein the second enteric coating releases the dexlansoprazole at a pH of about 6.75.

5. The use of claim 4, wherein the second enteric coating comprises a mixture of a methacrylic copolymer Type B and a methacrylic copolymer Type A in a ratio of 3:1.

6. The use of any preceding claim, wherein the first solid particle comprises a protective layer between the dexlansoprazole and the first enteric coating.

7. The use of any preceding claim, wherein the second solid particle comprises a protective layer between the dexlansoprazole and the second enteric coating.

8. The use of claims 6 or 7, wherein the protective layer is sucrose, hypromellose, a non-enteric coating or any combinations thereof.

9. The use of claim 8, wherein the non-enteric coating is hydroxypropylcellulose.

10. The use of any preceding claim, wherein the first solid particle is present in the pharmaceutical composition in an amount of about 25% of the pharmaceutical composition and the second solid particle is present in the pharmaceutical composition in an amount of about 75% of the pharmaceutical composition.

11. The use of any preceding claim, wherein the first solid particle is a granule.

12. The use of any preceding claim, wherein the second solid particle is a granule.

13. The use of any preceding claim, wherein the pharmaceutical composition is a tablet or capsule.

WHAT IS CLAIMED:

1. Use of a pharmaceutical composition a therapeutically effective amount of a dosage form comprising a proton pump inhibitor, wherein said pharmaceutical composition is capable of being administered to a patient independent of the intake of food in the manufacture of a medicament for treating a gastrointestinal disorder in a patient.

2. Use of a pharmaceutical composition comprising a therapeutically effective amount of:
(a) a first solid particle, wherein said first solid particle comprises an active agent and a first enteric coating, wherein the first enteric coating releases the active agent from the solid particle at a pH of about 5.0 to about 5.5; and
(b) a second solid particle, wherein said second solid particle comprises an active agent and a second enteric coating, wherein the second enteric coating releases the active agent from the solid particle at a pH of about 6.2 to about 6.8;
wherein the first solid particle comprises from about 15% to about 50% by weight of the pharmaceutical composition and the second solid particle comprises from about 50% to about 85% by weight of the pharmaceutical composition; and
further wherein said pharmaceutical composition is capable of being administered to a patient independent of the intake of food in the manufacture of a medicament for treating a gastrointestinal disorder in a patient.

3. The use of claim 2, wherein the active agent in the first solid particle is dexlansoprazole.

4. The use of claim 2, wherein the active agent in the second solid particle is dexlansoprazole.

5. The use of claim 2, wherein the active agent in the first solid particle and the second solid particle is dexlansoprazole.

6. The use of claim 2, wherein the first enteric coating has a pH of about 5.5.

7. The use of claim 6, wherein the first enteric coating comprises a methacrylic acid copolymer dispersion.

8. The use of claim 2, wherein the second enteric coating has a pH of about 6.75.

9. The use of claim 8, wherein the second enteric coating comprises a mixture of a methacrylic copolymer Type B and a methacrylic copolymer Type A in a ratio of 3:1.

10. The use of claim 2, wherein the first solid particle comprises a protective layer between the active agent and the first enteric coating.

11. The use of claim 2, wherein the second solid particle comprises a protective layer between the active agent and the second enteric coating.

12. The use of claims 10 or 11, wherein the protective layer is sucrose, hypromellose, a non-enteric coating or any combinations thereof.

13. The use of claim 12, wherein the non-enteric coating is hydroxypropylcellulose.

14. The use of claim 2, wherein the first solid particle comprises about 25% of the pharmaceutical composition and the second solid particle comprises about 75% of the pharmaceutical composition.

15. The use of claim 2, wherein the first solid particle is a granule.

16. The use of claim 2, wherein the second solid particle is a granule.

17. The use of claim 2, wherein the pharmaceutical composition is a tablet or capsule.

18. The use of claim 2, wherein the gastrointestinal condition is heartburn, inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding peptic ulcer, a duodenal ulcer, infectious enteritis, colitis, diverticulitis, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, Helicobacter pylori associated disease, short-bowel syndrome, hypersecretory states associated with systemic mastocytosis or basophilic leukemia or hyperhistaminemia or combinations of any of the above disorders.